Founded in 2015, the investment firm is headquartered in Beijing, managing three venture capital funds in RMB with a total of 1,400 MM RMB (~200MM USD), and is still raising a fund in U.S. dollars of 50MM~100MM USD, with the confirmed limited partners from well-known Chinese big pharma.
The firm has 20+ portfolio companies, and is open to investing globally in the angel to series B round, with a focus on series A round. For therapeutics, the firm is interested in pre-clinical to phase III, mainly the pre-clinical stage. For each fund, the firm selects 10-15 companies to invest in, and each investment ranging from 10MM RMB (1,420,000 USD) to 40MM RMB (5,700,000 USD); the rest of the fund will be used to invest the future rounds of those selected companies to help them grow.
The firm has a general interest in the early-stage life science technology assets, including therapeutics, diagnostics, medical devices, and digital health, especially MRA, Gene diagnostics, AI in healthcare, cell/gene therapy. The firm prefers projects in novel developing areas, but has less interest in technologies that are already in the field of very fierce competition, with big players already in.
The firm has no specific requirements for the Company & Management Team.
If you are interested in more information about this investor and other investors tracked by LSN, please email 4dmeetsai@lifesciencenation.com.
Next Phase Newsletter 
Leave a Reply